ES2191618T3 - Suspension de ziprasidona. - Google Patents

Suspension de ziprasidona.

Info

Publication number
ES2191618T3
ES2191618T3 ES00920981T ES00920981T ES2191618T3 ES 2191618 T3 ES2191618 T3 ES 2191618T3 ES 00920981 T ES00920981 T ES 00920981T ES 00920981 T ES00920981 T ES 00920981T ES 2191618 T3 ES2191618 T3 ES 2191618T3
Authority
ES
Spain
Prior art keywords
suspension
ziprasidona
ziprasidone
polysorbate
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00920981T
Other languages
English (en)
Inventor
Daniel Ray Arenson
Hong Qi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2191618T3 publication Critical patent/ES2191618T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

Una suspensión que comprende base libre de ziprasidona o una sal de adición de ácido de ziprasidona, agua, un polisorbato, un agente de viscosidad y dióxido de silicio coloidal.
ES00920981T 1999-05-27 2000-05-08 Suspension de ziprasidona. Expired - Lifetime ES2191618T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
ES2191618T3 true ES2191618T3 (es) 2003-09-16

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00920981T Expired - Lifetime ES2191618T3 (es) 1999-05-27 2000-05-08 Suspension de ziprasidona.

Country Status (50)

Country Link
EP (1) EP1181018B1 (es)
JP (1) JP3942827B2 (es)
KR (1) KR100477782B1 (es)
CN (1) CN1196486C (es)
AP (1) AP1409A (es)
AR (1) AR022643A1 (es)
AT (1) ATE234097T1 (es)
AU (1) AU777413B2 (es)
BG (1) BG65367B1 (es)
BR (1) BR0010990A (es)
CA (1) CA2371550C (es)
CO (1) CO5170458A1 (es)
CR (1) CR6506A (es)
CU (1) CU23223B7 (es)
CZ (1) CZ20014230A3 (es)
DE (1) DE60001649T2 (es)
DK (1) DK1181018T3 (es)
DZ (1) DZ3049A1 (es)
EA (1) EA003907B1 (es)
EE (1) EE04704B1 (es)
ES (1) ES2191618T3 (es)
GC (1) GC0000190A (es)
GE (1) GEP20033113B (es)
GT (1) GT200000081A (es)
HK (1) HK1046366B (es)
HN (1) HN2000000071A (es)
HR (1) HRP20010878B1 (es)
HU (1) HUP0201297A3 (es)
IL (2) IL145950A0 (es)
IS (1) IS2396B (es)
MA (1) MA26741A1 (es)
MX (1) MXPA01012124A (es)
MY (1) MY127891A (es)
NO (1) NO320296B1 (es)
NZ (1) NZ514764A (es)
OA (1) OA11946A (es)
PA (1) PA8495801A1 (es)
PE (1) PE20010127A1 (es)
PL (1) PL196867B1 (es)
RS (1) RS50089B (es)
SI (1) SI1181018T1 (es)
SK (1) SK284590B6 (es)
SV (1) SV2001000085A (es)
TN (1) TNSN00112A1 (es)
TR (1) TR200103392T2 (es)
TW (1) TWI263498B (es)
UA (1) UA59491C2 (es)
UY (1) UY26166A1 (es)
WO (1) WO2000072847A1 (es)
ZA (1) ZA200109692B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
WO2004037289A2 (en) * 2002-10-25 2004-05-06 Pfizer Products Inc. Novel injectable depot formulations
EP1562546A1 (en) * 2002-10-25 2005-08-17 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
EA200800092A1 (ru) * 2005-06-20 2008-06-30 Элан Фарма Интернэшнл Лимитед Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
KR20020048307A (ko) 2002-06-22
NO20015755L (no) 2002-01-23
PE20010127A1 (es) 2001-02-06
BG65367B1 (bg) 2008-04-30
CN1196486C (zh) 2005-04-13
JP3942827B2 (ja) 2007-07-11
DZ3049A1 (fr) 2004-03-27
EE200100633A (et) 2003-02-17
MA26741A1 (fr) 2004-12-20
JP2003500449A (ja) 2003-01-07
GT200000081A (es) 2001-11-16
IS6134A (is) 2001-10-30
CA2371550A1 (en) 2000-12-07
EE04704B1 (et) 2006-10-16
HRP20010878B1 (en) 2007-03-31
CR6506A (es) 2004-03-24
SK284590B6 (sk) 2005-07-01
HRP20010878A2 (en) 2003-06-30
HN2000000071A (es) 2001-02-02
NZ514764A (en) 2004-04-30
OA11946A (en) 2006-04-13
IS2396B (is) 2008-08-15
AU777413B2 (en) 2004-10-14
BR0010990A (pt) 2002-03-05
KR100477782B1 (ko) 2005-03-21
BG106153A (bg) 2002-06-28
DK1181018T3 (da) 2003-04-22
PA8495801A1 (es) 2001-12-14
SK16782001A3 (sk) 2002-09-10
NO320296B1 (no) 2005-11-21
IL145950A (en) 2007-12-03
HK1046366B (zh) 2005-07-29
AP1409A (en) 2005-06-13
ZA200109692B (en) 2002-11-26
NO20015755D0 (no) 2001-11-26
TNSN00112A1 (fr) 2005-11-10
CU23223B7 (es) 2007-08-30
YU76701A (sh) 2005-07-19
MY127891A (en) 2006-12-29
AP2001002346A0 (en) 2001-12-31
EP1181018B1 (en) 2003-03-12
CO5170458A1 (es) 2002-06-27
EA200101131A1 (ru) 2002-04-25
RS50089B (sr) 2009-01-22
GC0000190A (en) 2006-03-29
IL145950A0 (en) 2002-07-25
EP1181018A1 (en) 2002-02-27
ATE234097T1 (de) 2003-03-15
CN1352560A (zh) 2002-06-05
AR022643A1 (es) 2002-09-04
PL196867B1 (pl) 2008-02-29
UY26166A1 (es) 2000-12-29
CZ20014230A3 (cs) 2002-08-14
HK1046366A1 (en) 2003-01-10
PL352826A1 (en) 2003-09-08
UA59491C2 (uk) 2003-09-15
DE60001649T2 (de) 2003-08-21
TR200103392T2 (tr) 2002-11-21
HUP0201297A2 (en) 2002-08-28
SI1181018T1 (en) 2003-06-30
SV2001000085A (es) 2001-11-08
GEP20033113B (en) 2003-11-25
WO2000072847A1 (en) 2000-12-07
CA2371550C (en) 2007-01-02
MXPA01012124A (es) 2002-06-04
DE60001649D1 (de) 2003-04-17
AU4138500A (en) 2000-12-18
HUP0201297A3 (en) 2005-09-28
EA003907B1 (ru) 2003-10-30
TWI263498B (en) 2006-10-11

Similar Documents

Publication Publication Date Title
ES2191618T3 (es) Suspension de ziprasidona.
BRPI0407352A (pt) Composição para o cuidado oral, e, métodos para efetuar a estabilidade aumentada em uma composição oral contendo enzimas, e para a preparação de uma composição para o cuidado oral aquosa
ES2193903T1 (es) Soles de silice estables de alta superficie especifica y actividad mejorada.
RU2001126719A (ru) Дигетерозамещенные ингибиторы металлопротеазы
ATE363267T1 (de) Mittel zur verbesserung der hauttextur
AR036844A1 (es) Un tisu absorbente suave que contiene polisiloxanos amino-funcionales derivatizados.
BR0008445A (pt) Emulsões pit
DE60019507D1 (de) Wässrige Dispersionen von Percarbonsäure
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
DE69808923T2 (de) Wässrige kolloidale dispersionen aus sulfo-polyharnstoff
DE60215685D1 (de) Stabilisierte hydroxylaminlösungen
ATE352206T1 (de) Flüssiges brotverbesserungsmittel
AR023815A1 (es) Solucion oral de prucalopride
ATE232099T1 (de) Stabile xylometazolin- und oxymetazolinlösung
ATE291068T1 (de) Emulgiertes gel
DK0848713T3 (da) Pyridiniminyl-1,2-benzisoxazoler og -benzisothiazoler som antipsykotiske midler
DE69836040D1 (de) Korrekturflüssigkeit
DK1156829T3 (da) Stabil formulering indeholdende fumagillin
DK1222418T3 (da) Forbindelsesstykke
NO20020252L (no) Tixocortolpivalat-suspensjon, munnvask basert derpå og forpakninger inneholdende samme
ITBO990180A0 (it) Sistema di telecomunicazioni per lo scambio di informazioni riservate tra una persona fisica ed un sistema informativo .
BR0116082A (pt) Agentes antilipêmicos
BR0112460A (pt) Método para tratamento de sépsis
IT1313802B1 (it) Metodo e dispositivo per l'invio sicuro di messaggi e/o datipersonali e/o riservati
MA25447A1 (fr) Concept d'affichage publicitaire sur le sol.